Filing Flows › Comparisons › VTRS vs VRTX
Viatris vs Vertex Pharmaceuticals: VTRS and VRTX compared
Viatris is the larger company: $3.7B of revenue in its latest quarter (Q3 2026) against $3.4B for Vertex Pharmaceuticals (Q3 2026). Vertex Pharmaceuticals is growing faster (+12% against -0.3% a year earlier). Vertex Pharmaceuticals is more profitable, with an operating margin of 20.7% against 7.0%.
Where the money goes: VTRS and VRTX
Viatris (VTRS) · Q3 2026
Viatris, Q3 2026: revenue $3.7B (-0.3% year over year), operating margin 7.0%, net loss $325M, operating cash flow $899M. The chart follows the revenue to costs, profit and cash.
Vertex Pharmaceuticals (VRTX) · Q3 2026
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
| Viatris (VTRS) | Vertex Pharmaceuticals (VRTX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $3.7B | $3.4B |
| Revenue growth, Y/Y | -0.3% | +12% |
| Operating margin | 7.0% | 20.7% |
| Net earnings | −$325M | $654M |
| Net margin | -8.7% | 19.0% |
| Operating cash flow | $899M | $643M |
| Free cash flow | $814M | $546M |
| Market value | $22.1B | $139.6B |
| P/E | — | 35.2× |
| Analysts’ mean target | $21.00 | $592.36 |
Where the revenue comes from
Viatris
- Brands: $2.5B (66%)
- Lipitor: $452M (12%)
- EpiPen® Auto-Injectors: $156M (4%)
- Lyrica ®: $114M (3%)
Vertex Pharmaceuticals
- Total CF product revenues, net: $3.3B (95%)
- CASGEVY: $99.2M (3%)
- JOURNAVX: $58.3M (2%)
Questions
Which is bigger, Viatris or Vertex Pharmaceuticals?
Viatris is the larger company: $3.7B of revenue in its latest quarter (Q3 2026) against $3.4B for Vertex Pharmaceuticals (Q3 2026).
Is Viatris or Vertex Pharmaceuticals growing faster?
Vertex Pharmaceuticals is growing faster (+12% against -0.3% a year earlier).
Which is more profitable, Viatris or Vertex Pharmaceuticals?
Vertex Pharmaceuticals is more profitable, with an operating margin of 20.7% against 7.0%.
More: Viatris earnings · how Viatris makes money · Vertex Pharmaceuticals earnings · how Vertex Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.